RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Ridgeback Capital
R

Ridgeback Capital portfolio

Ridgeback Capital has 2 portfolio companies on record at Recent Funding.

Type: Crossover fund.
Portfolio on Recent Funding: 2.
Deals, last 12 months: 0.
Rounds led: 1 of 2.
Capital in their rounds: $262M.
Latest deal: Arbor Biotechnologies · Nov 9, 2021.
About this page

It is a crossover fund based in US, founded in 2006. It led 1 of the 2 rounds it joined. Its most recent investment on record is Arbor Biotechnologies's $215M Series B+ round in November 2021, alongside Tao Capital, TCG Crossover, Vertex Pharmaceuticals and 6 others. By category, its portfolio leans toward Health and bio (2). It has co-invested with T. Rowe Price, S32 and Tao Capital.

About Ridgeback Capital

Firm type: Crossover fund.
Headquarters: US.
Founded: 2006.
Stages: Seed, Late Stage.
Sectors: Biotech, Digital Health, Healthtech, Medical Devices.
Portfolio companies: 157.
Exits: 18.
Rounds led: 0.

What Ridgeback Capital invests in

How Ridgeback Capital invests

StageDealsCapital in rounds
Series B+ 2 100%$262M

Ridgeback Capital portfolio companies

CompanyRound with Ridgeback CapitalTotal raisedLatest raise
AArbor Biotechnologies
Health and bio
Series B+ · $215M$289MMar 18, 2025
Series B+
AAcepodia
Health and bio
Series B+ · $47M · lead$256MJun 7, 2023
Series B+

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.

Share is of the 2 rounds on Recent Funding that name Ridgeback Capital. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists Ridgeback Capital, which is a subset of its real portfolio. API: /api/v1/investors/ridgeback-capital (get a free API key). More: the most active VC firms and new venture capital funds.